DMAC
Price
$3.92
Change
-$0.06 (-1.51%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
168.53M
19 days until earnings call
HMTXF
Price
$0.10
Change
-$0.00 (-0.00%)
Updated
Jul 11 closing price
Capitalization
14.3M
Interact to see
Advertisement

DMAC vs HMTXF

Header iconDMAC vs HMTXF Comparison
Open Charts DMAC vs HMTXFBanner chart's image
DiaMedica Therapeutics
Price$3.92
Change-$0.06 (-1.51%)
Volume$3.15K
Capitalization168.53M
Hemostemix
Price$0.10
Change-$0.00 (-0.00%)
Volume$600
Capitalization14.3M
DMAC vs HMTXF Comparison Chart in %
Loading...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DMAC vs. HMTXF commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Hold and HMTXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (DMAC: $3.93 vs. HMTXF: $0.10)
Brand notoriety: DMAC and HMTXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 438% vs. HMTXF: 2%
Market capitalization -- DMAC: $168.53M vs. HMTXF: $14.3M
DMAC [@Biotechnology] is valued at $168.53M. HMTXF’s [@Biotechnology] market capitalization is $14.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileHMTXF’s FA Score has 1 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • HMTXF’s FA Score: 1 green, 4 red.
According to our system of comparison, HMTXF is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 5 TA indicator(s) are bullish while HMTXF’s TA Score has 2 bullish TA indicator(s).

  • DMAC’s TA Score: 5 bullish, 4 bearish.
  • HMTXF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than HMTXF.

Price Growth

DMAC (@Biotechnology) experienced а +7.08% price change this week, while HMTXF (@Biotechnology) price change was +0.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +40.41%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMAC($169M) has a higher market cap than HMTXF($14.3M). HMTXF YTD gains are higher at: 38.203 vs. DMAC (-27.624). HMTXF has higher annual earnings (EBITDA): -2.79M vs. DMAC (-29.04M). DMAC has more cash in the bank: 36.3M vs. HMTXF (965K). DMAC has less debt than HMTXF: DMAC (316K) vs HMTXF (4.69M). DMAC (0) and HMTXF (0) have equivalent revenues.
DMACHMTXFDMAC / HMTXF
Capitalization169M14.3M1,182%
EBITDA-29.04M-2.79M1,041%
Gain YTD-27.62438.203-72%
P/E RatioN/AN/A-
Revenue00-
Total Cash36.3M965K3,762%
Total Debt316K4.69M7%
FUNDAMENTALS RATINGS
DMAC vs HMTXF: Fundamental Ratings
DMAC
HMTXF
OUTLOOK RATING
1..100
2469
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5141
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HMTXF's Valuation (4) in the null industry is somewhat better than the same rating for DMAC (59) in the Biotechnology industry. This means that HMTXF’s stock grew somewhat faster than DMAC’s over the last 12 months.

HMTXF's Profit vs Risk Rating (100) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's SMR Rating (98) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

HMTXF's Price Growth Rating (41) in the null industry is in the same range as DMAC (51) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to DMAC’s over the last 12 months.

HMTXF's P/E Growth Rating (100) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACHMTXF
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMROF0.300.02
+7.64%
Amaero Ltd
ASBFF27.88N/A
N/A
Associated British Foods plc
CHYCY1.95N/A
N/A
Chiyoda Corp.
TOEAF22.42N/A
N/A
Toei Animation Co., Ltd.
NZERF0.16N/A
N/A
New Zealand Energy Corp.

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
-1.26%
WHWK - DMAC
46%
Loosely correlated
-5.13%
HUMA - DMAC
31%
Poorly correlated
+1.26%
ELDN - DMAC
30%
Poorly correlated
-0.79%
CGON - DMAC
30%
Poorly correlated
+9.13%
DSGN - DMAC
30%
Poorly correlated
-3.13%
More

HMTXF and

Correlation & Price change

A.I.dvisor tells us that HMTXF and DMAC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HMTXF and DMAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HMTXF
1D Price
Change %
HMTXF100%
N/A
DMAC - HMTXF
22%
Poorly correlated
-1.26%
BIVI - HMTXF
21%
Poorly correlated
+10.12%
AGEN - HMTXF
21%
Poorly correlated
+5.66%
DVHGF - HMTXF
21%
Poorly correlated
N/A
FDMT - HMTXF
12%
Poorly correlated
+2.35%
More